Hepatitis C virus and type 2 diabetes

Negro, Francesco; Alaei, Maryam

doi:10.3748/wjg.15.1537

Cited by 140 publications

(120 citation statements)

References 118 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…IR and obesity are likely to activate a cascade of events leading to excessive release of free fatty acids from the liver. When plasma uptake and "de novo" synthesis of free fatty acids overcome hepatocyte ability to oxidize and export these compounds as triglycerides, they accumulate in the liver parenchyma, causing steatosis (39). In this study, we observed that IR patients had higher levels of HCV--induced liver fibrosis, compared with subjects without IR.…”

Section: Resultssupporting

confidence: 59%

Insulin resistance in non-diabetic patients with chronic hepatitis C: what does it mean?

Souza

Pace²,

Chebli³

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objectives: To determine the prevalence of insulin resistance (IR) in non-diabetic patients with chronic hepatitis C, and to assess the association between IR, laboratory parameters and histological findings. Subjects and methods: Eighty-two patients had their serum analyzed for glucose, lipid profile, C-reactive protein (CRP), ferritin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), HOMA-IR, viral load and HCV genotype. Patients with HOMA-IR levels > 2.5 were considered as carriers of insulin resistance. Results: IR was observed in 27% of patients and was associated with age, waist circumference and body mass index. IR patients were more likely to have more advanced hepatic fibrosis and necroinflammatory activity, higher levels of aminotransferases and liver steatosis than patients without IR. Conclusions: Insulin resistance is often present in patients with chronic hepatitis C, and this parameter is associated with more advanced HCV-related hepatic fibrosis. Arq Bras Endocrinol Metab. 2011;55(6):412-8 Keywords Chronic hepatitis C; liver fibrosis; insulin resistance; HOMA-IR RESUMO Objetivos: Em portadores de hepatite crônica C não diabéticos, verificar a prevalência de resistência insulínica (RI) e analisar a associação desta com os parâmetros laboratoriais e histológicos. Sujeitos e métodos: Foram incluídos no estudo 82 pacientes, e amostras de sangue foram coletadas para determinação de glicose, perfil lipídico, alanina aminotransferase (ALT), aspartato aminotransferase (AST), ferritina, HOMA-IR, carga viral e genótipo do VHC. HOMA--IR superior a 2,5 foi considerado resistência insulínica. Resultados: RI foi observada em 27% dos pacientes e foi associada a idade, circunferência abdominal e índice de massa corpórea. Quando comparado a pacientes sem RI, aqueles com HOMA-IR superior a 2,5 apresentaram graus mais acentuados de fibrose hepática e atividade necroinflamatória, maiores níveis de aminotransferases e esteatose hepática mais frequente. Conclusões: É comum a presença de RI em portadores de hepatite crônica C e esta se associa com graus mais avançados de fibrose hepática induzida pelo vírus da hepatite C. Arq Bras Endocrinol Metab. 2011;55(6):412-8 Descritores

show abstract

Section: Resultssupporting

confidence: 59%

Insulin resistance in non-diabetic patients with chronic hepatitis C: what does it mean?

Souza

Pace²,

Chebli³

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…The prevalence of diabetes mellitus was reported to be higher in the patients with HCV-related cirrhosis (23.6%) than in those with HBV-related cirrhosis (9.4%) (Negro and Alaei, 2009). The prevalence of diabetes mellitus is also associated closely with the ChildPugh score and increasing age.…”

Section: Diabetic Patients With Chronic Liver Diseasementioning

confidence: 99%

Milk thistle in liver diseases: past, present, future

Abenavoli

Capasso²,

Milić

et al. 2010

Phytotherapy Research

458

335

View full text Add to dashboard Cite

Silybum marianum or milk thistle (MT) is the most well‐researched plant in the treatment of liver disease. The active complex of MT is a lipophilic extract from the seeds of the plant and is composed of three isomer flavonolignans (silybin, silydianin, and silychristin) collectively known as silymarin. Silybin is a component with the greatest degree of biological activity and makes up 50% to 70% of silymarin. Silymarin is found in the entire plant but it is concentrated in the fruit and seeds. Silymarin acts as an antioxidant by reducing free radical production and lipid peroxidation, has antifibrotic activity and may act as a toxin blockade agent by inhibiting binding of toxins to the hepatocyte cell membrane receptors. In animals, silymarin reduces liver injury caused by acetaminophen, carbon tetrachloride, radiation, iron overload, phenylhydrazine, alcohol, cold ischaemia and Amanita phalloides. Silymarin has been used to treat alcoholic liver disease, acute and chronic viral hepatitis and toxin‐induced liver diseases. Copyright © 2010 John Wiley & Sons, Ltd.

show abstract

“…19,20 Several studies, from different countries, had reported that 13-33% of patients with HCV infection had diabetes, mostly T2DM, 21 compared with the prevalence of 4-10% for non-HCV control population. 22 These data suggested that patients with HCV were 3 times more likely to develop DM than individuals who were HCV negative. We found 9.4% of our study subjects were anti-HCV positive.…”

Section: Discussionmentioning

confidence: 83%